Abdul Mannan: Rethinking Myeloid Precursor Disease in 2025
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, posted on LinkedIn:
”From Observation to Interception: Rethinking Myeloid Precursor Disease in 2025
Over the past few years, clonal haematopoiesis has moved from being a “benign curiosity of ageing” to a genuinely important clinical entity. The more we study it, the clearer it becomes that these precursor states don’t just sit quietly in the background. They shape two major fronts of disease: progression to MDS/AML and cardiovascular inflammation.
I’ve put together this infographic to make sense of the evolving landscape and the “4-C” spectrum we now recognise: CHIP, CCUS, CMUS, and CCMUS.
Why this matters
We’re no longer just observing clones; we’re learning when they behave, when they misbehave, and when they need closer follow-up. The old focus on blasts and cytopenias alone doesn’t cut it anymore. There’s a whole inflammatory story unfolding underneath.
Key points from the graphic
CHIP
Somatic mutation, normal counts, no cytopenia. Often found incidentally. Low annual progression risk, but a surprisingly strong link to cardiovascular disease. The heart always wants a cameo role.
CCUS
Somatic mutation plus persistent cytopenia. No MDS-defining features, but some cases progress rapidly. Think of this as CHIP that has decided to cause trouble.
CMUS
Somatic mutation plus persistent monocytosis. This sits on the path towards CMML and carries a high inflammatory burden. A reminder that monocytes are never shy when inflammation is involved.
CCMUS
Cytopenia + monocytosis + mutation. Highest overall risk. The “all-in-one” precursor deserves careful attention.
A Two-Front Battle
The infographic highlights what we’re all seeing in clinics and literature:
1. Front 1: Haematological progression
High-risk mutations (TP53, U2AF1, splicing genes) and VAF >10% increase the likelihood of evolving into MDS/AML.
2. Front 2: Systemic inflammation and cardiovascular disease
Mutations in TET2, JAK2, ASXL1, DNMT3A are themselves independent risk factors for:
• coronary artery disease
• venous thrombosis and stroke
• heart failure (both reduced and preserved EF)
It’s not often that haematology, cardiology, and immunology all fight for space on the same slide.
Where this takes us
We’re shifting from passive observation to interception. Early identification, structured follow-up, mutation-informed risk stratification, and collaboration across specialties will define the next decade of care.
If you’re teaching trainees, designing services, or thinking about where haematology is heading, this framework gives a clean, practical way to have those conversations.
Happy to share the high-resolution version, teaching notes, or a breakdown for your MDT or journal club.
Keep moving – one clone at a time.”
Stay updated with Hemostasis Today.
-
Sep 17, 2026, 13:09Mehak Trehan: New Perspectives on Anemia Management in CKD
-
Sep 17, 2026, 10:08WFH 2027 Comprehensive Care Summit Opens Abstract Submissions – World Federation of Hemophilia
-
Sep 17, 2026, 09:56Marianne Yee: MySCDstory Expands Access to Multilingual Sickle Cell Education
-
Sep 17, 2026, 09:36Enewa Onoja: Platelet Satellitism Phenomenon, Three Misleading Counts
-
Sep 17, 2026, 09:22Emmanuel J Favaloro: Hemostasis and Thrombosis in Exercise and Athletes
-
Sep 17, 2026, 09:18Updated Iron Deficiency Diagnostic Guidelines – American Society of Hematology
-
Sep 17, 2026, 09:14Angela Weyand: ASH 2026 Iron Deficiency Guidelines
-
Sep 17, 2026, 08:18Anirban Sen Gupta: From Flow to Clot Insights Into Hemostasis and Thrombosis
-
Sep 17, 2026, 08:03Aya Sherif: HEMO COP – Building a Collaborative Future for Hemophilia Care